LON:VRP Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisBuy This Stock About Verona Pharma plc (VRP.L) (LON:VRP) 30 days 90 days 365 days Advanced Chart Get VRP alerts:Sign Up Key Stats Today's Range N/A50-Day Range 55▼ 5552-Week Range N/AVolume70,791 shsAverage Volume150,610 shsMarket Capitalization£228 millionAssets Under ManagementN/ADividend YieldN/ANet Expense Ratio0.00%Aggregate RatingN/A ETF OverviewVerona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.Read More… Receive VRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter. Email Address VRP ETF News HeadlinesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Alphatec Holdings (ATEC), Verona Pharma (VRNA) and DENTSPLY SIRONA (XRAY)February 28, 2025 | markets.businessinsider.comCanaccord raises Verona Pharma target to $72; maintains buyFebruary 13, 2025 | msn.comTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.May 28, 2025 | Paradigm Press (Ad)Verona Pharma price target raised to $72 from $44 at CanaccordFebruary 12, 2025 | markets.businessinsider.comVerona Pharma stock soars to all-time high of $62.09February 12, 2025 | msn.comVerona Pharma Keeps Hitting New HighsFebruary 4, 2025 | msn.comSee More Headlines VRP ETF - Frequently Asked Questions How were Verona Pharma plc (VRP.L)'s earnings last quarter? Verona Pharma plc (VRP.L) (LON:VRP) released its earnings results on Thursday, February, 27th. The company reported ($30.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($30.80) by $0.50. How do I buy shares of Verona Pharma plc (VRP.L)? Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Verona Pharma plc (VRP.L) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL) and Amicus Therapeutics (FOLD). Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (LON:VRP) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s Bitcoin Reserve is No Accident…For the first time in history, we have a president who understands crypto's potential to bypass the banking sy...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc (VRP.L) Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma plc (VRP.L) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
